Macomics launches fundraising for Prof. Jeffrey Pollard Memorial Fund

Macomics Ltd, a leader in macrophage drug discovery, is delighted to announce that it has launched the Macomics Hyper-Triathlon Challenge, in honour of its co-founder Prof. Jeffrey Pollard, who passed away earlier this year, to raise funds for the newly established Jeff Pollard’s memorial fund.

The new charitable fund, managed by the University of Edinburgh where Prof. Pollard was Director of the MRC Centre for Reproductive Health, will be used to organise scientific meetings focused on macrophage biology, and to fund travel and enrichment grants aimed at early career researchers.  

Macomics was founded on the breakthrough research of Prof. Pollard and Dr. Luca Cassetta, from the University of Edinburgh, to develop cancer therapeutics against novel targets on macrophages.

Dr Luca Cassetta, VP immunology and co-founder of Macomics said, “To celebrate Jeff’s achievements as a world leader in macrophage biology and a mentor, and to commemorate his impact on our company, Macomics team decided to help raise money for the newly established Jeff Pollard’s memorial fund.”

Macomics has two laboratories, one located in Roslin Innovation Centre, near Edinburgh and the other on Cambridge Science Park.

“Although our two sites are separated by 460km in a straight line, we are one team working for the benefits of cancer patients. To prove that this distance is not a barrier, the Macomics Hyper-Triathlon Challenge will consist of 46km of swimming, 460km of running/walking, and 4600km of cycling over the slightly more than 4 months period” explained Cassetta.

As well as linking Macomics’ staff on two sites, the challenge reflects the company’s goal to connect macrophage biology from cancer research to cancer treatments. with cancer: the challenge started on September 24th, which was World Cancer Research Day and finishes on February 4th, which is World Cancer Day.

More news and updates